What are palbociclib (Ibrance) and ribociclib (Kisqali)?
Palbociclib (Ibrance) and ribociclib (Kisqali) are oral cancer drugs used to treat certain hormone receptor–positive, HER2-negative breast cancers. Both drugs are CDK4/6 inhibitors, meaning they block cyclin-dependent kinases 4 and 6 to slow tumor-cell growth [1][2].
How do Ibrance and Kisqali work, and how are they taken?
Both drugs target the same pathway (CDK4/6), but they are different medicines with different dosing schedules. Palbociclib and ribociclib are typically used together with hormone therapy (endocrine therapy) rather than alone in many patients [1][2].
What are the main differences between Ibrance and Kisqali?
They differ in the specific drug (palbociclib vs ribociclib), dosing regimen, and prescribing details such as how often the drug is taken and how it may interact with other medications. They are also studied and authorized for overlapping but not identical sets of patient populations and treatment settings [1][2].
Which patients are they used for?
Both are used in HR-positive, HER2-negative breast cancer, including advanced or metastatic disease, often combined with endocrine therapy depending on the stage and prior treatments. Eligibility depends on the tumor subtype (HR status and HER2 status) and clinical context [1][2].
What side effects do people ask about?
Common side effects for CDK4/6 inhibitors include low white blood cell counts (neutropenia), fatigue, nausea, and anemia. The exact risk profile and likelihood of specific side effects can vary between palbociclib and ribociclib [1][2].
Are there important drug–drug interactions or safety monitoring?
Because both drugs are metabolized and can affect blood counts, clinicians monitor for blood-count changes and also review other medicines for interactions. Ribociclib in particular is often associated with heart rhythm monitoring needs in prescribing information, while palbociclib has different monitoring emphases—so the chosen CDK4/6 inhibitor depends on the patient’s overall health and current medications [1][2].
How do they compare to each other in practice?
In clinical practice, the choice between Ibrance and Kisqali usually comes down to factors like dosing schedule preference, patient comorbidities, potential drug interactions, and how the patient fits the specific labeled indications for each drug [1][2].
Can they be used after one stops working?
CDK4/6 inhibitors are sometimes continued or sequenced depending on prior exposure, timing, and disease progression patterns, but the best approach depends on individual treatment history and available labeled options.
---
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali